Symbols / DTIL Stock $8.20 +4.33% Precision BioSciences, Inc.

Healthcare • Biotechnology • United States • NCM
DTIL (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Michael Amoroso
Exch · Country NCM · United States
Market Cap 211.61M
Enterprise Value 97.44M
Income -46.61M
Sales 34.26M
FCF (ttm) -21.97M
Book/sh 3.83
Cash/sh 4.67
Employees 68
Insider 10d —
IPO Mar 28, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -4.28
PEG —
P/S 6.18
P/B 2.14
P/C —
EV/EBITDA -1.92
EV/Sales 2.84
Quick Ratio 12.97
Current Ratio 13.32
Debt/Eq 31.23
LT Debt/Eq —
EPS (ttm) -2.17
EPS next Y -1.92
EPS Growth —
Revenue Growth 52.61%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-05
ROA -22.41%
ROE -62.71%
ROIC —
Gross Margin 100.00%
Oper. Margin 36.57%
Profit Margin -133.45%
Shs Outstand 25.81M
Shs Float 19.58M
Insider Own 5.09%
Instit Own 61.09%
Short Float 4.96%
Short Ratio 3.41
Short Interest 1.25M
52W High 8.82
vs 52W High -7.03%
52W Low 3.53
vs 52W Low 132.29%
Beta 1.31
Impl. Vol. 12.50%
Rel Volume 0.75
Avg Volume 267.05K
Volume 201.52K
Target (mean) $32.00
Tgt Median $24.50
Tgt Low $19.00
Tgt High $60.00
# Analysts 4
Recom Strong_buy
Prev Close $7.86
Price $8.20
Change 4.33%
About

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$32.00
Mean price target
2. Current target
$8.20
Latest analyst target
3. DCF / Fair value
$-15.33
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.20
Low
$19.00
High
$60.00
Mean
$32.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-05-21 reit HC Wainwright & Co. Buy → Buy $60
2025-03-28 reit HC Wainwright & Co. Buy → Buy $60
2025-03-19 reit HC Wainwright & Co. Buy → Buy $60
2025-02-19 reit HC Wainwright & Co. Buy → Buy $60
2025-01-10 reit HC Wainwright & Co. Buy → Buy $60
2025-01-10 up BMO Capital Market Perform → Outperform $34
2024-05-30 reit HC Wainwright & Co. Buy → Buy $60
2024-05-16 reit HC Wainwright & Co. Buy → Buy $60
2024-04-30 init Guggenheim — → Buy $19
2024-04-17 reit HC Wainwright & Co. Buy → Buy $60
2024-03-28 main HC Wainwright & Co. Buy → Buy $60
2024-02-14 reit HC Wainwright & Co. Buy → Buy $3
News
RSS: Latest DTIL news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-18 KELLY JOHN ALEXANDER Chief Financial Officer — 8,149 $3.84 $31,292
2026-02-18 SMITH J JEFFERSON Officer — 4,925 $3.84 $18,912
2026-02-18 SCIMECA DARIO JOSEPH General Counsel — 4,925 $3.84 $18,912
2026-02-18 AMOROSO MICHAEL Chief Executive Officer — 20,559 $3.84 $78,947
2026-02-17 KELLY JOHN ALEXANDER Chief Financial Officer — 27,584 — —
2026-02-17 SMITH J JEFFERSON Officer — 16,667 — —
2026-02-17 SCIMECA DARIO JOSEPH General Counsel — 16,667 — —
2026-02-17 AMOROSO MICHAEL Chief Executive Officer — 67,797 — —
2026-01-22 AMOROSO MICHAEL Chief Executive Officer — 34,799 $4.17 $145,112
2026-01-21 SMITH J JEFFERSON Officer — 29,166 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
34.26
-50.12%
68.70
+40.98%
48.73
+94.15%
25.10
Operating Revenue
34.26
-50.12%
68.70
+40.98%
48.73
+94.15%
25.10
Operating Expense
86.41
-8.90%
94.86
+2.59%
92.46
+5.79%
87.41
Research And Development
54.17
-9.04%
59.56
+11.59%
53.38
+15.73%
46.12
Selling General And Administration
32.24
-8.67%
35.30
-9.69%
39.09
-5.32%
41.28
General And Administrative Expense
32.24
-8.67%
35.30
-9.69%
39.09
-5.32%
41.28
Other Gand A
32.24
-8.67%
35.30
-9.69%
39.09
-5.32%
41.28
Total Expenses
86.41
-8.90%
94.86
+2.59%
92.46
+5.79%
87.41
Operating Income
-52.15
-99.33%
-26.16
+40.18%
-43.74
+29.81%
-62.31
Total Operating Income As Reported
-52.15
-99.33%
-26.16
+40.18%
-43.74
+29.81%
-62.31
EBITDA
-42.43
-413.72%
13.53
+142.21%
-32.04
+48.97%
-62.79
Normalized EBITDA
-53.11
-239.38%
-15.65
+50.45%
-31.58
+38.57%
-51.41
Reconciled Depreciation
2.75
-39.85%
4.58
-44.55%
8.26
-8.32%
9.00
EBIT
-45.19
-604.94%
8.95
+122.21%
-40.30
+43.87%
-71.80
Total Unusual Items
10.67
-63.42%
29.17
+6428.42%
-0.46
+95.95%
-11.38
Total Unusual Items Excluding Goodwill
10.67
-63.42%
29.17
+6428.42%
-0.46
+95.95%
-11.38
Special Income Charges
-0.46
-4.82%
-0.44
+5.42%
-0.46
+95.76%
-10.87
Impairment Of Capital Assets
0.04
0.00
0.00
-100.00%
10.84
Write Off
—
—
0.00
-100.00%
10.84
Net Income
-45.72
-737.98%
7.17
+111.69%
-61.32
+45.07%
-111.64
Pretax Income
-46.61
-750.33%
7.17
+116.85%
-42.53
+41.67%
-72.91
Net Non Operating Interest Income Expense
2.82
-43.45%
4.98
-8.71%
5.46
+130.99%
2.36
Interest Expense Non Operating
1.42
-20.20%
1.78
-20.09%
2.23
+100.72%
1.11
Net Interest Income
2.82
-43.45%
4.98
-8.71%
5.46
+130.99%
2.36
Interest Expense
1.42
-20.20%
1.78
-20.09%
2.23
+100.72%
1.11
Interest Income Non Operating
4.24
-37.32%
6.76
-12.01%
7.69
+121.31%
3.47
Interest Income
4.24
-37.32%
6.76
-12.01%
7.69
+121.31%
3.47
Other Income Expense
2.72
-90.40%
28.35
+767.48%
-4.25
+67.24%
-12.96
Other Non Operating Income Expenses
-2.67
-1133.33%
0.26
-77.47%
1.15
—
Gain On Sale Of Security
11.13
-62.41%
29.61
+2486.03%
1.15
+324.51%
-0.51
Gain On Sale Of Business
—
—
—
0.00
Tax Rate For Calcs
0.00
-100.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
6.13
0.00
0.00
Net Income Including Noncontrolling Interests
-45.72
-737.98%
7.17
+111.69%
-61.32
+45.07%
-111.64
Net Income From Continuing Operation Net Minority Interest
-46.61
-750.33%
7.17
+116.85%
-42.53
+41.67%
-72.91
Net Income From Continuing And Discontinued Operation
-45.72
-737.98%
7.17
+111.69%
-61.32
+45.07%
-111.64
Net Income Continuous Operations
-46.61
-750.33%
7.17
+116.85%
-42.53
+41.67%
-72.91
Net Income Discontinuous Operations
0.89
0.00
+100.00%
-18.79
+51.48%
-38.73
Normalized Income
-57.28
-260.70%
-15.88
+62.25%
-42.07
+31.63%
-61.52
Net Income Common Stockholders
-45.72
-737.98%
7.17
+111.69%
-61.32
+45.07%
-111.64
Diluted EPS
—
1.04
+106.52%
-15.96
+58.11%
-38.10
Basic EPS
—
1.05
+106.58%
-15.96
+58.11%
-38.10
Basic Average Shares
—
6.83
+77.88%
3.84
+31.11%
2.93
Diluted Average Shares
—
6.88
+79.20%
3.84
+31.11%
2.93
Diluted NI Availto Com Stockholders
-45.72
-737.98%
7.17
+111.69%
-61.32
+45.07%
-111.64
Earnings From Equity Interest
-5.28
-387.45%
-1.08
+78.02%
-4.93
-212.29%
-1.58
Gain On Sale Of PPE
-0.42
+3.44%
-0.44
+5.42%
-0.46
-1436.67%
-0.03
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
154.42
+13.22%
136.39
-14.64%
159.78
-32.91%
238.17
Current Assets
118.74
+25.00%
94.99
-30.34%
136.36
-31.51%
199.10
Cash Cash Equivalents And Short Term Investments
115.58
+33.92%
86.31
-26.03%
116.68
-38.45%
189.58
Cash And Cash Equivalents
110.82
+29.02%
85.90
-26.38%
116.68
-38.45%
189.58
Other Short Term Investments
4.76
+1053.03%
0.41
0.00
—
Receivables
0.00
-100.00%
1.70
-86.73%
12.80
+1677.50%
0.72
Accounts Receivable
0.00
-100.00%
0.23
-74.58%
0.90
+25.14%
0.72
Other Receivables
—
1.47
—
—
Prepaid Assets
3.11
-51.72%
6.44
+7.76%
5.98
-0.80%
6.03
Assets Held For Sale Current
0.00
-100.00%
0.17
-65.30%
0.49
-68.70%
1.56
Other Current Assets
0.04
-87.80%
0.37
-11.93%
0.42
-65.88%
1.23
Total Non Current Assets
35.68
-13.82%
41.40
+76.75%
23.42
-40.04%
39.06
Net PPE
7.23
-28.97%
10.18
-30.29%
14.60
+5.97%
13.78
Gross PPE
35.92
-6.10%
38.26
-4.57%
40.09
+12.46%
35.65
Accumulated Depreciation
-28.69
-2.19%
-28.08
-10.15%
-25.49
-16.55%
-21.87
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
4.04
+0.00%
4.04
+2.20%
3.96
+0.20%
3.95
Construction In Progress
0.00
-100.00%
0.01
-87.14%
0.07
-86.54%
0.52
Other Properties
19.82
-10.64%
22.18
-8.06%
24.12
+25.39%
19.23
Leases
12.06
+0.30%
12.03
+0.69%
11.95
-0.01%
11.95
Goodwill And Other Intangible Assets
1.17
+87.46%
0.62
+55.50%
0.40
-45.28%
0.73
Other Intangible Assets
1.17
+87.46%
0.62
+55.50%
0.40
-45.28%
0.73
Investments And Advances
0.74
-76.79%
3.21
+0.00%
3.21
-32.48%
4.75
Long Term Equity Investment
—
—
0.00
-100.00%
2.17
Other Non Current Assets
26.54
+16.44%
22.79
+10028.89%
0.23
-98.21%
12.57
Total Liabilities Net Minority Interest
62.17
-22.29%
80.00
-43.23%
140.92
-20.71%
177.74
Current Liabilities
8.91
-40.50%
14.98
-70.03%
49.99
-16.22%
59.66
Payables And Accrued Expenses
2.01
-39.60%
3.33
-26.45%
4.53
+82.46%
2.48
Payables
0.30
-77.44%
1.31
-55.80%
2.97
+354.52%
0.65
Accounts Payable
0.30
-77.44%
1.31
-55.80%
2.97
+354.52%
0.65
Current Accrued Expenses
1.71
-14.98%
2.02
+29.48%
1.56
-14.78%
1.83
Pensionand Other Post Retirement Benefit Plans Current
4.75
-8.39%
5.18
+4.10%
4.98
-2.47%
5.10
Current Debt And Capital Lease Obligation
1.51
+14.17%
1.32
-94.39%
23.55
+1303.16%
1.68
Current Debt
—
—
22.41
—
Other Current Borrowings
—
—
22.41
—
Current Capital Lease Obligation
1.51
+14.17%
1.32
+16.50%
1.13
-32.48%
1.68
Current Deferred Liabilities
0.00
-100.00%
2.96
-75.43%
12.04
-73.95%
46.19
Current Deferred Revenue
0.00
-100.00%
2.96
-75.43%
12.04
-73.95%
46.19
Other Current Liabilities
0.65
-70.41%
2.19
-55.28%
4.90
+16.48%
4.21
Total Non Current Liabilities Net Minority Interest
53.26
-18.09%
65.02
-28.50%
90.93
-22.99%
118.07
Liabilities Heldfor Sale Non Current
—
—
0.13
-92.55%
1.72
Long Term Debt And Capital Lease Obligation
27.30
-4.96%
28.73
+271.94%
7.72
-66.83%
23.28
Long Term Debt
22.40
+0.37%
22.32
—
22.22
Long Term Capital Lease Obligation
4.90
-23.53%
6.40
-17.08%
7.72
+629.27%
1.06
Non Current Deferred Liabilities
10.00
-69.97%
33.30
-59.92%
83.08
-10.54%
92.87
Non Current Deferred Revenue
10.00
-69.97%
33.30
-59.92%
83.08
-10.54%
92.87
Other Non Current Liabilities
0.26
+33.51%
0.19
+51.56%
0.13
-36.32%
0.20
Stockholders Equity
92.25
+63.58%
56.39
+198.99%
18.86
-68.79%
60.43
Common Stock Equity
92.25
+63.58%
56.39
+198.99%
18.86
-68.79%
60.43
Capital Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Common Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
24.12
+193.03%
8.23
+96.36%
4.19
+12.49%
3.73
Ordinary Shares Number
24.09
+193.66%
8.20
+96.99%
4.16
+12.58%
3.70
Treasury Shares Number
0.03
-0.35%
0.03
+0.00%
0.03
0.00%
0.03
Additional Paid In Capital
621.39
+15.11%
539.81
+5.96%
509.44
+4.03%
489.70
Retained Earnings
-528.19
-9.48%
-482.46
+1.46%
-489.63
-14.32%
-428.31
Treasury Stock
0.95
+0.00%
0.95
+0.00%
0.95
+0.00%
0.95
Total Equity Gross Minority Interest
92.25
+63.58%
56.39
+198.99%
18.86
-68.79%
60.43
Total Capitalization
114.65
+45.66%
78.71
+317.34%
18.86
-77.18%
82.66
Working Capital
109.83
+37.27%
80.01
-7.37%
86.37
-38.06%
139.44
Invested Capital
114.65
+45.66%
78.71
+90.72%
41.27
-50.07%
82.66
Total Debt
28.81
-4.12%
30.05
-3.91%
31.27
+25.27%
24.96
Capital Lease Obligations
6.40
-17.09%
7.72
-12.78%
8.86
+223.57%
2.74
Net Tangible Assets
91.08
+63.31%
55.77
+202.10%
18.46
-69.08%
59.70
Tangible Book Value
91.08
+63.31%
55.77
+202.10%
18.46
-69.08%
59.70
Available For Sale Securities
0.74
-76.79%
3.21
+0.00%
3.21
+24.46%
2.58
Derivative Product Liabilities
15.70
+461.34%
2.80
0.00
—
Investmentin Financial Assets
0.74
-76.79%
3.21
+0.00%
3.21
+24.46%
2.58
Investments In Other Ventures Under Equity Method
—
—
—
—
Non Current Note Receivables
0.00
-100.00%
4.60
-7.78%
4.99
-31.02%
7.23
Notes Receivable
—
0.00
-100.00%
11.90
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-65.84
-12.66%
-58.45
+30.52%
-84.11
-83.84%
-45.75
Cash Flow From Continuing Operating Activities
-65.84
-12.66%
-58.45
+30.52%
-84.11
-83.84%
-45.75
Net Income From Continuing Operations
-45.72
-737.98%
7.17
+111.69%
-61.32
+45.07%
-111.64
Depreciation Amortization Depletion
2.75
-39.85%
4.58
-44.55%
8.26
-8.32%
9.00
Depreciation
2.75
-39.85%
4.58
-44.55%
8.26
-8.32%
9.00
Depreciation And Amortization
2.75
-39.85%
4.58
-44.55%
8.26
-8.32%
9.00
Other Non Cash Items
2.43
+445.03%
-0.70
-378.91%
-0.15
-132.67%
0.45
Stock Based Compensation
10.19
-19.18%
12.60
-10.23%
14.04
-26.86%
19.20
Asset Impairment Charge
0.04
0.00
-100.00%
0.64
-94.40%
11.44
Operating Gains Losses
-6.28
+77.65%
-28.09
-851.56%
-2.95
-275.19%
1.69
Gain Loss On Investment Securities
-11.13
+62.41%
-29.61
—
—
Unrealized Gain Loss On Investment Securities
—
-0.26
+77.47%
-1.15
—
Change In Working Capital
-29.24
+45.84%
-54.00
-30.16%
-41.49
-272.07%
24.11
Change In Receivables
1.70
-81.03%
8.95
+5046.41%
-0.18
+21.98%
-0.23
Changes In Account Receivables
0.23
-65.92%
0.67
+471.27%
-0.18
+21.98%
-0.23
Change In Prepaid Assets
3.33
+817.89%
-0.46
-144.15%
1.05
+209.25%
-0.96
Change In Payables And Accrued Expense
-0.74
+64.84%
-2.10
-238.99%
1.51
+885.62%
0.15
Change In Payable
-0.74
+64.84%
-2.10
-238.99%
1.51
+885.62%
0.15
Change In Account Payable
-0.74
+64.84%
-2.10
-238.99%
1.51
+885.62%
0.15
Change In Other Working Capital
-30.79
+45.85%
-56.87
-29.41%
-43.95
-260.64%
27.36
Change In Other Current Assets
0.34
+229.39%
-0.26
-114.95%
1.75
+22.43%
1.43
Change In Other Current Liabilities
-3.08
+5.46%
-3.26
-95.21%
-1.67
+54.10%
-3.64
Investing Cash Flow
-0.63
-194.88%
-0.21
-103.69%
5.83
+275.63%
-3.32
Cash Flow From Continuing Investing Activities
-0.63
-194.88%
-0.21
-103.69%
5.83
+275.63%
-3.32
Net PPE Purchase And Sale
-0.02
+90.00%
-0.19
+89.73%
-1.85
+44.26%
-3.32
Purchase Of PPE
-0.09
+66.00%
-0.25
+87.23%
-1.96
+41.04%
-3.32
Sale Of PPE
0.07
+10.00%
0.06
-43.93%
0.11
0.00
Capital Expenditure
-0.70
-154.55%
-0.28
+87.93%
-2.28
+31.36%
-3.32
Net Business Purchase And Sale
—
0.00
-100.00%
8.00
0.00
Gain Loss On Sale Of Business
-0.85
0.00
+100.00%
-8.45
0.00
Net Intangibles Purchase And Sale
-0.61
-2360.00%
-0.03
+92.21%
-0.32
0.00
Purchase Of Intangibles
-0.61
-2360.00%
-0.03
+92.21%
-0.32
0.00
Financing Cash Flow
95.16
+88.63%
50.45
+836.51%
5.39
-94.33%
94.98
Cash Flow From Continuing Financing Activities
95.16
+88.63%
50.45
+836.51%
5.39
-94.33%
94.98
Net Issuance Payments Of Debt
0.00
+100.00%
-0.04
0.00
-100.00%
19.80
Issuance Of Debt
0.00
-100.00%
22.47
0.00
-100.00%
19.80
Repayment Of Debt
0.00
+100.00%
-22.50
0.00
0.00
Long Term Debt Issuance
0.00
-100.00%
22.47
0.00
0.00
Long Term Debt Payments
0.00
+100.00%
-22.50
0.00
0.00
Net Long Term Debt Issuance
0.00
+100.00%
-0.04
0.00
0.00
Short Term Debt Issuance
—
—
0.00
-100.00%
19.80
Net Short Term Debt Issuance
—
—
0.00
-100.00%
19.80
Net Common Stock Issuance
94.94
+88.99%
50.24
+907.58%
4.99
-93.29%
74.34
Proceeds From Stock Option Exercised
0.22
-12.45%
0.25
-37.91%
0.40
-51.98%
0.83
Net Other Financing Charges
—
—
—
—
Changes In Cash
28.68
+449.39%
-8.21
+88.74%
-72.90
-258.77%
45.91
Beginning Cash Position
108.47
-7.04%
116.68
-38.45%
189.58
+31.96%
143.66
End Cash Position
137.15
+26.45%
108.47
-7.04%
116.68
-38.45%
189.58
Free Cash Flow
-66.54
-13.32%
-58.72
+32.03%
-86.39
-76.05%
-49.07
Interest Paid Supplemental Data
1.35
-22.04%
1.74
-13.88%
2.02
+144.90%
0.82
Common Stock Issuance
94.94
+88.99%
50.24
+907.58%
4.99
-93.29%
74.34
Earnings Losses From Equity Investments
5.28
+387.45%
1.08
-78.02%
4.93
+212.29%
1.58
Issuance Of Capital Stock
94.94
+88.99%
50.24
+907.58%
4.99
-93.29%
74.34
Sale Of Business
—
0.00
-100.00%
8.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category